Clinical trial
Randomized Amifostine For SCCHN
NCT00095927 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00095927 |
|---|---|
| Title | Randomized Amifostine For SCCHN |
| Official title | Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH MedImmune LLC Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia |
| Intervention type | Drug, Radiation |
| Interventions | Amifostine, Carboplatin, Paclitaxel, radiation |
| Enrollment | 58 |
| Start date | May 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Nov 9, 2004 |
| Last update posted | Jan 4, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: